A Dose Escalation Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Trial Profile

A Dose Escalation Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs RG 6146 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Roche; Tensha Therapeutics
  • Most Recent Events

    • 23 Jun 2017 Planned number of patients changed from 68 to 51.
    • 23 Jun 2017 Planned End Date changed from 31 Aug 2017 to 30 Apr 2018.
    • 23 Jun 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top